awmsg logo



ocrelizumab (Ocrevus®)


Reference No. 1096

Excluded date:
08/02/2018


Appraisal information

ocrelizumab (Ocrevus®) intravenous infusion


Company: Roche Products Ltd
BNF category: Malignant disease and immunosupression
   
   
Submission Type: Unspecified
Status: Excluded

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

Indication

First-line treatment of primary progressive multiple sclerosis

AWMSG advice

Product meets AWMSG exclusion criteria due to NICE appraisal